Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Bristol myers Squibb Company
Bristol myers Squibb Company And Lexicon Pharmaceuticals Inc
Bristol myers Squibb Company And Albany Molecular Research Inc
Bristol myers Squibb Company_20100107
Bristol myers Squibb Company_20100121
Bristol myers Squibb Company_20131212
Bristol myers Squibb Company_20100128
Bristol myers Squibb Company_20100114

Bristol myers Squibb Company patents


Recent patent applications related to Bristol myers Squibb Company. Bristol myers Squibb Company is listed as an Agent/Assignee. Note: Bristol myers Squibb Company may have other listings under different names/spellings. We're not affiliated with Bristol myers Squibb Company, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Bristol myers Squibb Company-related inventors


Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer

Provided are methods for clinical treatment of cancer (e.g., advanced refractory solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-PD-1 antibody.... Bristol myers Squibb Company

Pyrrolidine gpr40 modulators

or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are GPR40 G protein-coupled receptor modulators which may be used as medicaments.... Bristol myers Squibb Company

Benzofurans substituted with secondary benzamide as hcv inhibitors

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and areuseful in treating those infected with HCV.... Bristol myers Squibb Company

Anti-csf1r antibody and anti pd-1 antibody combination therapy for cancer

Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.... Bristol myers Squibb Company

Enantioselective synthesis of pyrroloindole compounds

Compounds according to formula (I) or (II), wherein R1, R2, and R3 are as defined in the specification, are versatile intermediates for the synthesis of DNA minor groove binder-alkylators having a cyclopropapyrroloindole (CPI) or seco-CPI alkylating subunit.... Bristol myers Squibb Company

Immunomodulators

The present disclosure provides compounds which are immunomodulators and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.... Bristol myers Squibb Company

Immunoassay for soluble programmed death-1 (spd-1) protein

This disclosure provides a method for quantifying total soluble Programmed Death-1 (sPD-1) in a sample solution comprising the steps of performing a “sandwich” immunoassay on the sample solution and a series of reference solutions containing known quantities of sPD-1, wherein the immunoassay is performed using (a) a sPD-1 reference antigen... Bristol myers Squibb Company

Use of alkaline washes during chromatography to remove impurities

In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants, said method comprising: a) subjecting the mixture to a first chromatography matrix, wherein the protein of interest binds to the first chromatography... Bristol myers Squibb Company

Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.... Bristol myers Squibb Company

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's... Bristol myers Squibb Company

Benzodiazepine dimers, conjugates thereof, and methods of making and using

wherein the variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).... Bristol myers Squibb Company

Tableted compositions containing atazanavir

Disclosed are compressed tablets containing atazanavir sulfate, optionally with another active agents, e.g., anti-HIV agents, granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets, compositions comprising a plurality of the granules, processes for making the granules and tablets, and methods of treating... Bristol myers Squibb Company

Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer

There are disclosed compounds of formula (I) that modulate or inhibit the enzymatic activity of indoleamine-2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.... Bristol myers Squibb Company

Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors

or an enantiomer, diastereomer or a pharmaceutically-acceptable salt thereof, wherein X is N or C—R7, are useful as kinase modulators, including IRAK-4 modulation.... Bristol myers Squibb Company

Heterocyclic compounds useful as inhibitors of tnf

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is CR6 or N; W is: (i) —(CR3R3)1-4— or (ii) —(CR3R3)x-Y—(CR3R3)y-; and Y, R1, R2, R3, R5, R6, R7, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNFα, and... Bristol myers Squibb Company

Derivatives of uncialamycin, methods of synthesis and their use as antitumor agents

In one aspect, the present disclosure provides new analogs of uncialamycin. The present disclosure also provides novel synthetic pathways to obtaining uncialamycin and analogs thereof. Additionally, the present disclosure also describes methods of use of uncialamycin and analogs thereof. In another aspect, the present disclosure provides antibody-drug conjugates which may... Bristol myers Squibb Company

Compounds useful as immunomodulators

The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer... Bristol myers Squibb Company

Binding molecules to the human ox40 receptor

The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods... Bristol myers Squibb Company

Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use

where Hal, R1, R2, and R3 are as defined in the application, are potent anti-cancer agents that can be used in antibody-drug conjugates.... Bristol myers Squibb Company

Antibody polypeptides that antagonize cd40l

Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK... Bristol myers Squibb Company

Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to TL1A. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of... Bristol myers Squibb Company

Lactams as inhibitors of rock

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune,... Bristol myers Squibb Company

Use of phenolic antioxidants in cell culture for the production of proteins

The present invention relates to new methods and processes for culturing mammalian cells with the addition of phenolic antioxidants. Performance of the cell culturing methods and processes in their various aspects result in a higher viable cell density and higher protein titer.... Bristol myers Squibb Company

Device and testing and inspecting integrity of a container

An inspection device and method for testing and inspecting integrity of a container (200) is disclosed. The inspection device has an angled member (102) and a viewing member (104) secured to the angled member. Together, the angled and viewing members are configured to hold a container to be analyzed. The... Bristol myers Squibb Company

Benzothiazole and benzothiophene compounds

The present invention provides benzothiazole compounds or benzothiophene compounds of Formula I having the structure: wherein X1, X2, X3, X4, X5, Y, WR2, R3, R4, R5, R6, R7 and AA and other moieties are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof.... Bristol myers Squibb Company

Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using

and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).... Bristol myers Squibb Company

Bispecific egfr/igfir binding molecules

The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative... Bristol myers Squibb Company

Il-17a/f and il-23p19 bispecific antibodies and methods of using the same

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.... Bristol myers Squibb Company

Antibodies conjugatable by transglutaminase and conjugates made therefrom

An antibody has at a heavy chain thereof a C-terminal extension that includes at least one glutamine that is a substrate for transglutaminase, enabling the transglutaminase-mediated preparation antibody-drug conjugates using such antibody.... Bristol myers Squibb Company

Human fc-bearing igg antibodies to polyethylene glycol

Polyethylene glycol (PEG) is often conjugated with therapeutic proteins to enhance their PK properties. PEG may, however, be immunogenic, and the presence of PEG in food and cosmetics is believed to result in pre-existing anti-PEG antibodies in humans. Polyclonal and monoclonal antibodies reactive to PEG are provided for use in... Bristol myers Squibb Company

Benzofuran compounds for the treatment of hepatitis c

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV:... Bristol myers Squibb Company

Benzofurans substituted with primary benzamide as hcv inhibitors

Compounds of Formula (I), including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.... Bristol myers Squibb Company

Substituted benzofuran compounds for the treatment of hepatitis c

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV:... Bristol myers Squibb Company

Quinazolines as potassium ion channel inhibitors

wherein A, X, Y, Z, R1 and R24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, IKur-associated disorders, and other disorders mediated by ion channel function.... Bristol myers Squibb Company

Benzofurans substituted with bicyclic secondary benzamide as hcv inhibitors

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV: Formula (I)... Bristol myers Squibb Company

02/01/18 / #20180030057

Substituted imidazo[1,5-a]pyrazines as cgrp receptor antagonists

The disclosure generally relates to the novel compounds of formula I, including pharmaceutically acceptable salts, which arc CGRP-receptor antagonists. The disclosure also relates to pharmaceutical compositions and methods for using the compounds in the treatment of CGRP related disorders including migraine headaches, neurogenic vasodilation, neurogenic inflammation, thermal injury, circulatory shock,... Bristol myers Squibb Company

01/25/18 / #20180021436

Atazanavir sulfate formulations with improved ph effect

Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent, optionally with another active agent, e.g., anti-HIV agents, and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets, and methods of treating HIV.... Bristol myers Squibb Company

01/25/18 / #20180022723

Novel compounds for the treatment of hepatitis c

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Bristol myers Squibb Company

01/25/18 / #20180022753

Macrocycles as factor xia inhibitors

or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of fXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or... Bristol myers Squibb Company

01/25/18 / #20180023081

Lna oligonucleotides with alternating flanks

The present invention relates to LNA oligomers having two flanks, wherein one or both flanks comprise alternating LNA and DNA nucleosides.... Bristol myers Squibb Company

01/18/18 / #20180016247

Cyclic protein tyrosine kinase inhibitors

Novel cyclic compounds and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic and oncologic disorders.... Bristol myers Squibb Company

01/18/18 / #20180016336

Antibodies against tim3 and uses thereof

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides... Bristol myers Squibb Company

01/04/18 / #20180000788

Cyclic ureas as inhibitors of rock

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune,... Bristol myers Squibb Company

01/04/18 / #20180000790

[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

or a salt thereof, wherein R1, R2, R3, R4, R5, m, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory... Bristol myers Squibb Company

01/04/18 / #20180000807

Selective nr2b antagonists

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.... Bristol myers Squibb Company

01/04/18 / #20180002358

Tricyclic sulfones as ror gamma modulators

or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or... Bristol myers Squibb Company

01/04/18 / #20180002432

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region... Bristol myers Squibb Company

12/28/17 / #20170368172

Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment

This disclosure provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.... Bristol myers Squibb Company

12/28/17 / #20170369530

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.... Bristol myers Squibb Company

12/28/17 / #20170369549

Methods of treatment using ctla4 mutant molecules

The present invention provides soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig. The soluble CTLA4 molecules have a first amino acid sequence comprising the extracellular domain of CTLA4, where certain amino acid residues within the S25-R33... Bristol myers Squibb Company

12/28/17 / #20170370929

Positive allosteric modulators of the delta-opioid receptor

Described are the discovery, synthesis and pharmacological characterization of δ-opioid receptor-selective positive allosteric modulators (δ PAMs). These δ PAMs may increase the affinity and/or efficacy of the orthosteric agonists leu-enkephalin and SNC80, as measured by β-arrestin recruitment and adenylyl cyclase inhibition. The compounds may be useful pharmacological tools to probe... Bristol myers Squibb Company

12/21/17 / #20170360759

Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists

or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein all the variables are as defined herein. These compounds are selective LPA receptor inhibitors.... Bristol myers Squibb Company

12/21/17 / #20170362176

Carbazole derivatives

Disclosed are compounds of Formula (I): (I) or a salt thereof, wherein Q, R1a, R1b, R2a, R2b, R3, R4, R5a, R5b, R6a, R6c, R7a, R7b, R7c, and R7d are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising... Bristol myers Squibb Company

12/21/17 / #20170362219

Substituted dihydro-1h-pyrrolo[3,2-c]pyridin-4(5h)-ones as ripk3 inhibitors

Compounds having Formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK3 modulation. All the variables defined herein.... Bristol myers Squibb Company

12/21/17 / #20170362259

Process and intermediates for making tubulysin analogs

wherein n, R1, R2, and R3 are as defined in the specification. Compound B can be used to make tubulysin analogs that are, in turn, useful as anti-cancer agents, particularly when deployed in an antibody-drug conjugate.... Bristol myers Squibb Company

12/14/17 / #20170354718

Fibronectin based scaffold domain proteins that bind to myostatin

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates... Bristol myers Squibb Company

12/14/17 / #20170355673

Tricyclic atropisomer compounds

Disclosed are compounds of Formula (I): or a salt thereof, wherein Q is: or; and X, R1a, R1b, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful... Bristol myers Squibb Company

12/14/17 / #20170355689

Hepatitis c virus inhibitor

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Bristol myers Squibb Company

12/14/17 / #20170355698

Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors

Disclosed are compounds of Formula (I); or a salt thereof; wherein Qi is (i) Cl, Br, I, —CN, —CH3, or —CF3; or (ii) pyrazole, triazole, or pyridinyl, each substituted with R1; Q2 is pyridinyl, indazolyl, isoquinolinyl, or benzo[d]imidazolyl substituted with R2 and R3; and R1, R2, and R3 are defined... Bristol myers Squibb Company

12/14/17 / #20170355707

Bicyclic heteroaryl amine compounds

Disclosed are compounds of Formula (I) or a salt thereof; wherein: X is N or CH; Q1 is: (i) Cl, Br, I, —CN, —CH3, or —CF3; (ii) a 5-membered heteroaryl selected from pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, and thiadiazolyl; (iii) a 6?membered heteroaryl selected from pyridinyl, pyridazinyl, and... Bristol myers Squibb Company

12/14/17 / #20170355768

Combination of anti-cs1 and anti-pd1 antibodies to treat cancer (myeloma)

The invention described herein relates to therapeutic dosing regimens and combinations thereof for use in enhancing the therapeutic efficacy of anti-CS1 antibodies in combination with an anti-Programmed Death-1 (PD-1) antibody.... Bristol myers Squibb Company

11/30/17 / #20170340653

(r)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the NR2B NMDA receptor and may be useful for the treatment of various disorders of the central nervous system.... Bristol myers Squibb Company

11/30/17 / #20170342071

Macrocyclic factor xia inhibitors condensed with heterocycles

or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using... Bristol myers Squibb Company

11/23/17 / #20170334958

Protein scaffolds for antibody mimics and other binding proteins

Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.... Bristol myers Squibb Company

11/16/17 / #20170326247

Antibody-drug conjugates of tubulysin analogs with enhanced stability

The drug component of an antibody-drug conjugate having a structure according to formula (II), where Ab, m, n, R1, R2, R3, R4, and R5 are as defined in the application, exhibits unexpectedly improved stability.... Bristol myers Squibb Company

Patent Packs
11/16/17 / #20170326249

Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and uses

wherein m is 1, 2, 3, or 4 and Ab is an anti-glypican-3 antibody having heavy and light chain CDRs as disclosed herein.... Bristol myers Squibb Company

11/16/17 / #20170327457

Phenyl-(aza)cycloalkyl carboxylic acid gpr120 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.... Bristol myers Squibb Company

11/16/17 / #20170327498

Novel tricyclic compounds as anticancer agents

The present invention is directed to tricyclic compounds, pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.... Bristol myers Squibb Company

11/16/17 / #20170327558

Mammalian cell culture processes for protein production

The present invention describes methods and processes for the production of proteins by animal cell or mammalian cell culture. In one aspect, the methods comprise the growth of cells in a growth factor/protein/peptide free medium. In another aspect, the methods comprise the addition of growth factors during the production phase.... Bristol myers Squibb Company

11/16/17 / #20170328903

Methods for identifying patients at risk for costimulation blockade resistant rejection

The present invention provides methods utilizing changes in CD4+CD57+ T cells levels for determining the susceptibility of a transplant patient or patient in need thereof to costimulation blockade resistant rejection. These methods are useful for identifying effective drug regimens for the treatment of immune disorders associated with graft transplantation and/or... Bristol myers Squibb Company

11/09/17 / #20170320833

Hepatitis c virus inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.... Bristol myers Squibb Company

11/02/17 / #20170313742

Use of caprylic acid precipitation for protein purification

In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants, comprising: a) subjecting the mixture to a first chromatography step; b) recovering the protein of interest in an elution solution; c) adding... Bristol myers Squibb Company

10/26/17 / #20170304332

Substituted bicyclic compounds

and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in... Bristol myers Squibb Company

10/26/17 / #20170305880

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors

or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments.... Bristol myers Squibb Company

10/26/17 / #20170305929

Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

There are disclosed a series of quinuclidines having the Formula (I), which bind to the nicotinic α7 receptor and may be useful for the treatment of disorders of the central nervous system.... Bristol myers Squibb Company

10/26/17 / #20170306034

Methods of treating autoimmune disease using a domain antibody directed against cd40l

Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle... Bristol myers Squibb Company

10/26/17 / #20170306035

Antibodies against ox40 and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to OX40. Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies,... Bristol myers Squibb Company

10/05/17 / #20170283381

Dihydropyridinone mgat2 inhibitors

or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.... Bristol myers Squibb Company

10/05/17 / #20170283403

Diamide macrocycles that are fxia inhibitors

The present invention provides compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective Factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and... Bristol myers Squibb Company

10/05/17 / #20170283438

Substituted tetrahydrocarbazole and carbazole carboxamide compounds

R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's... Bristol myers Squibb Company

Patent Packs
10/05/17 / #20170283462

Immunomodulators

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.... Bristol myers Squibb Company

10/05/17 / #20170283463

Immunomodulators

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.... Bristol myers Squibb Company

09/28/17 / #20170275272

6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists

wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.... Bristol myers Squibb Company

09/28/17 / #20170275342

Protein scaffolds for antibody mimics and other binding proteins

Disclosed herein are proteins that include an immunoglobulin fold and that can be used as scaffolds. Also disclosed herein are nucleic acids encoding such proteins and the use of such proteins in diagnostic methods and in methods for evolving novel compound-binding species and their ligands.... Bristol myers Squibb Company

09/28/17 / #20170275357

Il-23p19 monoclonal antibodies and methods of using the same

The present invention relates to antagonizing the activity of IL-17A, IL-17F and IL-23 using bispecific antibodies that comprise a binding entity that is cross-reactive for IL-17A and IL-17F and a binding entity that binds IL-23p19. The present invention relates to novel bispecific antibody formats and methods of using the same.... Bristol myers Squibb Company

09/21/17 / #20170267666

Dihydropyridinone mgat2 inhibitors

or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.... Bristol myers Squibb Company

09/14/17 / #20170258777

Selective nr2b antagonists

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.... Bristol myers Squibb Company

09/14/17 / #20170258948

Novel pd-l1 binding polypeptides for imaging

Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.... Bristol myers Squibb Company

09/14/17 / #20170260145

Heterocyclic kinase inhibitors

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.... Bristol myers Squibb Company

09/14/17 / #20170260159

Tetrazolone-substituted dihydropyridinone mgat2 inhibitors

a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.... Bristol myers Squibb Company

09/14/17 / #20170260160

Indole carboxamide compounds

or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the... Bristol myers Squibb Company

09/14/17 / #20170260205

Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses

and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).... Bristol myers Squibb Company

09/14/17 / #20170260232

Tubulysin compounds, methods of making and use

where R1, R2 R3a, R3b, R4, R5, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.... Bristol myers Squibb Company

09/14/17 / #20170260237

Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions

The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.... Bristol myers Squibb Company

09/07/17 / #20170252432

Immunomodulators

The present disclosure provides novel macrocyclic compounds which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.... Bristol myers Squibb Company

09/07/17 / #20170253554

Cyclopropanecarboxylic acid gpr120 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein coupled receptor modulators which may be used as medicaments... Bristol myers Squibb Company

09/07/17 / #20170253665

Antibodies against cd73

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods... Bristol myers Squibb Company

08/31/17 / #20170247311

Cyclobutane containing carboxylic acid gpr120 modulators

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulators which may be used as medicaments.... Bristol myers Squibb Company

08/31/17 / #20170247343

Thioether triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase

The present invention provides compounds of Formula (I): wherein A, X and Y are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.... Bristol myers Squibb Company

08/31/17 / #20170247385

Furopyridine compounds for the treatment of hepatitis c

Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.... Bristol myers Squibb Company

08/31/17 / #20170247395

Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (par4) inhibitors for treating platelet aggregation

The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These... Bristol myers Squibb Company

08/31/17 / #20170247396

Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase

The present invention provides compounds of Formula (I): wherein A and R1 are each as defined in the specification, and compositions comprising any of such novel compounds. These compounds are myeloperoxidase (MPO) inhibitors and/or eosinophil peroxidase (EPX) inhibitors, which may be used as medicaments.... Bristol myers Squibb Company

08/31/17 / #20170247455

Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody

This disclosure provides a method for treating a subject afflicted with a cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an antibody or an antigen-binding portion thereof that specifically binds to PD-1; and (b) an antibody or an antigen-binding portion thereof that specifically binds to... Bristol myers Squibb Company

08/31/17 / #20170247466

Treatment of lung cancer using an anti-fucosyl-gm1 antibody

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject a therapeutically effective amount of an antibody or an antigen-binding portion thereof that specifically binds to Fucosyl-GM1.... Bristol myers Squibb Company








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Bristol myers Squibb Company in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bristol myers Squibb Company with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###